JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma. - Wikidata - wikimedia - TriplyDB

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

http://www.wikidata.org/entity/Q39149556

about

JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia Serum levels of interleukin-9 correlate with negative prognostic factors in extranodal NK/T-cell lymphoma.Genetic alterations of JAK/STAT cascade and histone modification in extranodal NK/T-cell lymphoma nasal type.Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines Disease-specific mutations in mature lymphoid neoplasms: recent advances.Recent advances in intestinal lymphomas.Targeting non-receptor tyrosine kinases using small molecule inhibitors: an overview of recent advances.Molecular Pathogenesis of Peripheral T Cell Lymphoma.Investigational drugs for T-cell lymphoma.A neutralized human LMP1-IgG inhibits ENKTL growth by suppressing the JAK3/STAT3 signaling pathway.Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells EBV-negative aggressive NK-cell leukemia/lymphoma: a clinical and pathological study from a single institution.Development of Selective Covalent Janus Kinase 3 Inhibitors.Long-term Benefit of PD-L1 Blockade in Lung Cancer Associated with JAK3 Activation.JAK/STAT pathway directed therapy of T-cell leukemia/lymphoma: Inspired by functional and structural genomics.The promise of Janus kinase inhibitors in the treatment of hematological malignancies.HiJAKing the epigenome in leukemia and lymphoma.Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type.Th17 cytokine differentiation and loss of plasticity after SOCS1 inactivation in a cutaneous T-cell lymphoma.Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma.Coexistence of systemic lupus erythematosus, tuberous sclerosis and aggressive natural killer-cell leukaemia: coincidence or correlated?JAK3-mediated phosphorylation of EZH2: a novel mechanism of non-canonical EZH2 activation and oncogenic function Resveratrol inhibits Extranodal NK/T cell lymphoma through activation of DNA damage response pathway Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma.Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells.Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.Advances in the understanding and management of T-cell prolymphocytic leukemia.Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.Role of Non Receptor Tyrosine Kinases in Hematological Malignances and its Targeting by Natural Products.Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma.Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma.Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target.Activated janus kinase 3 expression not by activating mutations identified in natural killer/T-cell lymphoma.STAT5 inhibition induces TRAIL/DR4 dependent apoptosis in peripheral T-cell lymphoma.Clinical and molecular characteristics of unicentric mediastinal Castleman disease.Aspects moléculaires des lymphomes T périphériques (2)Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma

P2860

Q26782539-746066A9-5D53-4A84-8592-C10B87D4061C Q34106849-F5EF12FE-DE14-43DB-B2B7-1D01940A7774 Q35145308-142AB236-1C23-4A5A-B3DA-88155EDD663D Q36232164-F451161C-F52B-417D-BA9A-6E886415C98F Q36372043-D06AB76A-7C66-4852-A283-10B9A07AE815 Q38201143-D1E45DAE-5908-4FB9-B67F-B9877744FB0A Q38339462-BE9F0A1A-E3E0-401A-8346-F1FF73879849 Q38554422-D8107433-3301-4AE5-9990-2EC868FF9F35 Q38597997-5BCD3634-4A72-4143-A782-93FB3C338223 Q38635909-B5F309D4-DFD0-4FF4-A520-BB24F99813DA Q38724665-A032F8B4-844D-4C9F-B00A-1B18AB3D84FE Q38741546-9646796B-5106-4A85-9D47-991DF71EDE72 Q38761793-34F5A4A0-09E9-4359-AE96-81871E333ACC Q38763094-66CE4B16-275C-44B5-BCE6-564B6F62F34C Q38870624-FB796CBB-57FF-43EF-B2E3-AC68B7C1794A Q39142126-AA6DD430-73D6-4A59-8175-FD014BD7FFF1 Q39170500-BF120202-A870-4CEB-A9D4-BDCAC90EEF90 Q39237403-019AE901-CDEA-432B-B182-2509804FE0AA Q40101543-EC324CC8-9CEE-4B3A-BE4F-A6AFBDAA80BA Q40688204-29545F38-9FD2-4581-A87E-2D1CF5FE4A5E Q40717160-5876614C-2AD9-4B1F-8E2D-64CAB81B4084 Q40766488-B83285E3-133E-4E36-BA5B-DFDDFAC64AF0 Q41576148-EA5EF9D1-726E-4086-9BF4-ED2D344F3FCE Q41674995-6AE6ADF2-60FE-44FE-9DD7-714911277265 Q42384344-C9CD55B3-DBDF-49A1-853E-D51595A29919 Q42827073-DC09ABCD-81A1-4BE1-B6A6-5E6B5FEDCB59 Q45328020-0BA8741A-4EAE-4EB4-8511-36D7017645A3 Q47113632-D0BFF15A-B44D-412F-B69A-65C14AC32C61 Q47240802-0B3B03A4-3C44-4C53-8872-D60389ED3526 Q49887894-0128660E-1295-4470-B16D-6CD61CF05039 Q50055394-C074A00A-CC52-4AA1-8BA0-3659531349B2 Q52560170-B6FA18BA-A35D-419B-BDC5-C08F578456E3 Q52718168-C11CB86D-25FD-44E8-8E3D-FC7BD1E49C59 Q54342283-F564E0C8-5F9B-4F19-B7AD-0C7AAECA4B3D Q54959839-C9990637-D59C-441B-8A53-8F7657DE74A9 Q55360160-A3AF3116-86ED-498C-BBCE-872643DB5955 Q57216715-E09CA99A-78A9-418D-BAEC-84766ECC2D46 Q58742961-6F15359C-1F16-4D40-B589-A6C68E8CC082

P2860

JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma.

http://www.wikidata.org/entity/Q39149556

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

JAK3 deregulation by activatin ...... natural killer cell lymphoma.

@en

JAK3 deregulation by activatin ...... natural killer cell lymphoma.

@nl

type

label

JAK3 deregulation by activatin ...... natural killer cell lymphoma.

@en

JAK3 deregulation by activatin ...... natural killer cell lymphoma.

@nl

prefLabel

JAK3 deregulation by activatin ...... natural killer cell lymphoma.

@en

JAK3 deregulation by activatin ...... natural killer cell lymphoma.

@nl

P1433

Q39149556-A9E5AD21-6103-4FAD-A7A0-1AA842AE0D58

P1476

Q39149556-3FE43CB0-1818-476D-9659-52CAC1A580A7

P2093

Q39149556-21DD4BFE-6A84-46DE-89A3-E827D8F2EE0B

Q39149556-2EA96D78-3834-4618-89BA-0F229E377AA5

Q39149556-43B978BA-F8D3-4315-B7D7-F824680CC557

Q39149556-9E7618A9-A8D6-4E7C-AC58-5F190C737D39

Q39149556-B10647D7-D9A7-4B63-BBBA-FF45E4EAD086

Q39149556-B9DABA55-F0E5-41F6-9FF6-D90B358A960D

Q39149556-C2D86789-C0B7-4922-B6B8-6D5198946BCB

Q39149556-D9FD1B08-FA56-4FC0-AF33-0AEC8804D997

Q39149556-DB5CB60E-12A1-49D7-AF0F-344183E3C353

Q39149556-E98861FB-54E6-40A4-B9C1-5F503F8DD407

P2860

Q39149556-088D8EEA-6D94-498C-98D9-5A3213C3B5AA

Q39149556-09F1E450-1392-427D-9788-844FEDECCB77

Q39149556-0CCFBBB6-965D-473D-A812-3FF647E53270

Q39149556-17BE3EF6-AA41-48B7-9F26-B66DEA26B221

Q39149556-2532CD72-E9D1-49AD-9AC2-80E2B3CDDDC0

Q39149556-30586496-CEA7-4487-BE1F-A09D114B955C

Q39149556-30A4C932-2698-48B7-BE8D-1147FB044996

Q39149556-368E31AB-7392-41F8-A162-C9BD187C739F

Q39149556-3D43579C-D341-41D4-B543-4A8C65DD8C5E

Q39149556-41FC9120-F879-4FAC-8751-988513840686

P2888

Q39149556-0DE00156-9A7D-4E39-B6E5-0A2599BEC433

P304

Q39149556-D65715F1-B409-438C-9057-5FCFAE34F191

P31

Q39149556-4BC51B45-B82C-4B24-8DDF-F1586AA1A817

P356

Q39149556-8CBF1F48-DC6F-4F12-B786-70F4B0DDC3D4

P433

Q39149556-8F783E04-95E3-4F6A-A534-A902EAF2E105

P478

Q39149556-D12ABCEA-3042-4ACB-9249-C64731476308

P50

Q39149556-1002AB25-513F-4838-9562-1360D571C007

Q39149556-8714B794-55D4-4B1A-8F7E-20B2C2CF6031

Q39149556-92F75C3C-E32F-4C73-9872-326F832C2784

Q39149556-F5D9C57D-5249-4804-A439-E6BA50367F64

P577

Q39149556-C478AB52-6684-46F2-A860-FAD188CCDB97

P698

Q39149556-2A826ADA-9E99-415A-9E86-92298DD93279

P356

P1433

P1476

JAK3 deregulation by activatin ...... e natural killer cell lymphoma

@en

P2093

A Aline-Fardin

http://www.w3.org/2001/XMLSchema#string

A Bouchekioua

http://www.w3.org/2001/XMLSchema#string

C Gespach

http://www.w3.org/2001/XMLSchema#string

D Jeziorowska

http://www.w3.org/2001/XMLSchema#string

L Douay

http://www.w3.org/2001/XMLSchema#string

L Scourzic

http://www.w3.org/2001/XMLSchema#string

O de Wever

http://www.w3.org/2001/XMLSchema#string

P Cervera

http://www.w3.org/2001/XMLSchema#string

P Coppo

http://www.w3.org/2001/XMLSchema#string

P Gaulard

http://www.w3.org/2001/XMLSchema#string

P2860

The genetic basis of early T-cell precursor acute lymphoblastic leukaemia.

IL-15 triggers an antiapoptotic pathway in human intraepithelial lymphocytes that is a potential new target in celiac disease-associated inflammation and lymphomagenesis

Cancer invasion and the microenvironment: plasticity and reciprocity

IL-9 and its receptor: from signal transduction to tumorigenesis

P53, N- and K-Ras, and beta-catenin gene mutations and prognostic factors in nasal NK/T-cell lymphoma from Hokkaido, Japan.

Clinical differences between nasal and extranasal natural killer/T-cell lymphoma: a study of 136 cases from the International Peripheral T-Cell Lymphoma Project.

Classification of lymphoid neoplasms: the microscope as a tool for disease discovery.

Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type

Malignant hematopoietic cell lines: in vitro models for the study of natural killer cell leukemia-lymphoma.

Dysregulated microRNAs affect pathways and targets of biologic relevance in nasal-type natural killer/T-cell lymphoma.

P2888

P304

338-348

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/LEU.2013.157

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

28

http://www.w3.org/2001/XMLSchema#string

P50

William Vainchenker

P577

2013-05-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23689514

http://www.w3.org/2001/XMLSchema#string